Because inflammation and systemic infection suppress erythropoiesis in the bone marrow, this finding may suggest the effectiveness of erythropoietin administration concomitant with antimicrobial therapy to maintain appropriate HGB levels in patients with CKD who experience sepsis during admission. This evidence concerns the gene EPO and chronic kidney disease.